
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Brand Name | Status | Last Update |
|---|---|---|
| seconal sodium | 2007-05-31 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hearing loss | D034381 | EFO_0004238 | H91.9 | — | — | — | — | 1 | 1 |
| Sensorineural hearing loss | D006319 | — | H90.5 | — | — | — | — | 1 | 1 |
| Drug common name | SECOBARBITAL |
| INN | secobarbital |
| Description | Secobarbital is a member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups. It has a role as an anaesthesia adjuvant, a GABA modulator and a sedative. It is functionally related to a barbituric acid. It is a conjugate acid of a secobarbital (1-). |
| Classification | Small molecule |
| Drug class | barbituric acid derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O |
| PDB | — |
| CAS-ID | 76-73-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL447 |
| ChEBI ID | 9073 |
| PubChem CID | 5193 |
| DrugBank | DB00418 |
| UNII ID | 1P7H87IN75 (ChemIDplus, GSRS) |






